These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12710216)

  • 1. Assays for in vitro and in vivo synergy.
    Teicher BA
    Methods Mol Med; 2003; 85():297-321. PubMed ID: 12710216
    [No Abstract]   [Full Text] [Related]  

  • 2. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.
    Leonetti C; Scarsella M; Riggio G; Rizzo A; Salvati E; D'Incalci M; Staszewsky L; Frapolli R; Stevens MF; Stoppacciaro A; Mottolese M; Antoniani B; Gilson E; Zupi G; Biroccio A
    Clin Cancer Res; 2008 Nov; 14(22):7284-91. PubMed ID: 19010844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
    Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
    Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination effects of SC144 and cytotoxic anticancer agents.
    Oshima T; Cao X; Grande F; Yamada R; Garofalo A; Louie S; Neamati N
    Anticancer Drugs; 2009 Jun; 20(5):312-20. PubMed ID: 19322070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
    Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
    Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
    Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic strategies for neoplasia.
    Talmadge JE
    Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
    Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
    Peer D; Dekel Y; Melikhov D; Margalit R
    Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Ballard P; Barlaam BC; Bradbury RH; Dishington A; Hennequin LF; Hickinson DM; Hollingsworth IM; Kettle JG; Klinowska T; Ogilvie DJ; Pearson SE; Scott JS; Suleman A; Whittaker R; Williams EJ; Wood R; Wright L
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6326-9. PubMed ID: 17869514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
    Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X; Sui M; Fan W
    Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
    Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
    Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental research on the antitumor effectiveness of Bac. intermedius RNAse].
    Kurinenko BM; Sobchuk LI; Khaĭbullina SA; Bulgakova RSh
    Eksp Onkol; 1988; 10(6):54-7. PubMed ID: 3243197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
    Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
    Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
    J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
    Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.